€420,000 grant enables exploration of emerging enzymes such as ene-reductase (ERED) and carboxylic acid reductase (CAR) enzymes in continuous flow reactors.
Will establish cell and gene therapy companies to advance the development of Mayo Clinic technologies through preclinical and early feasibility studies.
Protein-based vaccine uses purified pieces of the virus to spur an immune response, a technology that has been used to combat hepatitis B and influenza.
$76 million investment in Grand Island site increases capacity for raw materials used in the development and manufacturing of vaccines and biologic therapies.
TFBS will leverage scale-X carbo mid-scale fixed-bed bioreactor from Univercells for GMP viral vector operations at the CDMO’s New Taipei City facility.